Applied Molecular Transport Achieves Significant Milestone Technically

On Tuesday, Applied Molecular Transport (AMTI) achieved a significant technical milestone, as its Relative Strength (RS) Rating improved to 91, up from 87 the day before. When you’re looking for the best stocks to buy and watch, keep relative price strength in mind. With a score ranging from 1 (worst) to 99 (best), IBD’s unique rating distinguishes share price results. The ranking compares the price-output of a stock over the last 52 weeks to all other stocks in our database.

In the early stages of their moves, the market’s biggest winners have an RS Rating of 80 or higher, according to history. In a first-stage consolidation, Applied Molecular Transport stock has risen more than 5% past a 36.31 entry, indicating that it is now out of a proper buy range. It’s a risky stock, but when it rises sharply, it can pay off handsomely.

Look for a new opportunity to buy shares in the market, such as a three-week tight or a pullback to the 50-day or 10-week moving average. In its most recent quarterly report, the company recorded a 260 percent drop in earnings. Sales increased by 0%. On or about April 28, the company is scheduled to release its new earnings and sales figures.

In the Medical-Biomed/Biotech industry community, Applied Molecular Transport is ranked No. 204 by its peers. Horizon Therapeutics (HZNP), Alexion Pharmaceuticals (ALXN), and Halozyme Therapeutics (HALO) are among the group’s top five most highly ranked stocks. The Biotech Applied Molecular Transport Stock improves the Relative Strength Rating.